Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery

Isatin (1 indole 2, 3-dione) is a heterocyclic, endogenous lead molecule recognized in humans and different plants. The isatin nucleus and its derivatives are owed the attention of researchers due to their diverse pharmacological activities such as anticancer, anti-TB, antifungal, antimicrobial, ant...

Full description

Saved in:
Bibliographic Details
Published inPharmaceuticals (Basel, Switzerland) Vol. 15; no. 3; p. 272
Main Authors Cheke, Rameshwar S, Patil, Vaishali M, Firke, Sandip D, Ambhore, Jaya P, Ansari, Iqrar A, Patel, Harun M, Shinde, Sachin D, Pasupuleti, Visweswara Rao, Hassan, Md Imtaiyaz, Adnan, Mohd, Kadri, Adel, Snoussi, Mejdi
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 22.02.2022
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Isatin (1 indole 2, 3-dione) is a heterocyclic, endogenous lead molecule recognized in humans and different plants. The isatin nucleus and its derivatives are owed the attention of researchers due to their diverse pharmacological activities such as anticancer, anti-TB, antifungal, antimicrobial, antioxidant, anti-inflammatory, anticonvulsant, anti-HIV, and so on. Many research chemists take advantage of the gentle structure of isatins, such as NH at position 1 and carbonyl functions at positions 2 and 3, for designing biologically active analogues via different approaches. Literature surveys based on reported preclinical, clinical, and patented details confirm the multitarget profile of isatin analogues and thus their importance in the field of medicinal chemistry as a potent chemotherapeutic agent. This review represents the recent development of isatin analogues possessing potential pharmacological action in the years 2016-2020. The structure-activity relationship is also discussed to provide a pharmacophoric pattern that may contribute in the future to the design and synthesis of potent and less toxic therapeutics.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1424-8247
1424-8247
DOI:10.3390/ph15030272